ICCC - ImmuCell Announces Preliminary Unaudited Sales Results for Q3 2023 | Benzinga
PORTLAND, Maine, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023.
| Preliminary, Unaudited Total Sales Results: |
| 2023 |
| 2022 |
| $ Increase ($ Decrease) |
| % Increase (% Decrease) |
| During the Three-Month Periods Ended September 30, |
| $5.40 million |
| $4.80 million |
| $600,000 |
| 13% |
| During the Nine-Month Periods Ended September 30, |
| $12.38 million |
| $14.66 million |